Kornimate/medical-research-clean huggingface dataset:
ventilator hyperinflation and hemodynamics

Conditions: Respiratory Failure; Respiratory Disorders

Summary: ventilator hyperinflation (vhi) has been shown to be effective in improving respiratory mechanics, secretion removal, and gas exchange in mechanically ventilated patients; however, the literature is scarce concerning its safety and adverse effects. thus, the aim of this study is to compare the hemodynamic repercussions of vhi in volume-controlled mode. in a randomized, controlled and crossover design, 24 mechanically ventilated patients will undergo 2 modes of ventilator hyperinflation (with and without an inspiratory pause) and a control intervention. cardiac output, cardiac index, mean arterial pressure, pulmonary vascular resistance, systolic volume and other hemodynamic variables will be recorded during the interventions.

background: ventilator hyperinflation (vhi) has been shown to be effective in improving respiratory mechanics, secretion removal, and gas exchange in mechanically ventilated patients; however, the literature is scarce concerning its safety and adverse effects. thus, the aim of this study is to compare the hemodynamic repercussions of vhi in volume-controlled mode. methods: in a randomized, controlled and crossover design, 24 mechanically ventilated patients will undergo 2 modes of ventilator hyperinflation (with and without an inspiratory pause of 2 seconds) and a control intervention. for the vhi interventions, the inspiratory flow will be set at 20 lpm, and tidal volume will be increased until a peak pressure of 40cmh2o is achieved. during the control intervention, the patients will remain in volume-control ventilation with an inspiratory flow = 60lpm and tidal volume = 6ml/ibw. the interval between interventions (washout) will be of 10 minutes or more, according to the time needed to recover the cardiac index to baseline values (maximum difference of 10%). cardiac output, cardiac index, mean arterial pressure, pulmonary vascular resistance, systolic volume and other hemodynamic variables will be recorded during the interventions by using impedance cardiography.

Eligibility criteria:
inclusion criteria: * patients under mechanical ventilation for more than 48h exclusion criteria: * mucus hypersecretion (defined as the need for suctioning \< 2-h intervals), * absence of respiratory drive, * atelectasis, * severe bronchospasm, * positive end expiratory pressure \> 10cmh2o, * pao2-fio2 relationship \< 150, * mean arterial pressure \< 60mmhg, * inotrope requirement equivalent to \>15 ml/h total of adrenaline and noradrenalin, * intracranial pressure \> 20mmhg

Keywords: mechanical ventilation physiotherapy ventilator hyperinflation airway clearance technique
comparison of long-term outcomes following endoscopic or open surgery for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: no randomized trials have compared long-term outcomes following endoscopic and open carpal tunnel release in patients with carpal tunnel syndrome (cts). the investigators conducted a single-center randomized controlled trial between january 1998 and december 2002, including 128 patients (25 to 60 years) with clinically diagnosed and electrophysiologically confirmed idiopathic cts. the outcome measures included the validated cts symptom severity and functional status scales completed at baseline and 1 year postoperatively. the trial showed that the 1-year outcomes of open and endoscopic carpal tunnel release regarding symptoms and function were equivalent. this extended follow-up of the randomized trial will primarily measure the symptom outcomes at 10-15 years after surgery. a questionnaire will be sent by mail to the patients. the questionnaire will consist of the cts symptom severity and functional status scales, the 6-item cts symptoms scale (cts-6), the 11-item disabilities of the arm, shoulder and hand (quickdash), the 2-item palmar pain scale, and a visual analog scale about treatment satisfaction. the patients will also be asked about whether they had undergone further surgery for cts in the same or contralateral hand after their operation in the randomized trial. the completed questionnaires will be scanned into a database. the scores for the different scales will be calculated. analysis will include comparison between the open and endoscopic groups as well as within-group changes of scores from 1 year to 10-15 years.


Eligibility criteria:
inclusion criteria (original trial): * primary idiopathic carpal tunnel syndrome * age 25-60 years * currently employed * duration of symptoms of at least three months * inadequate response to six weeks' treatment with wrist splint * symptoms of classic or probable carpal tunnel syndrome according to the diagnostic criteria in the katz hand diagram, and nerve conduction test showing median neuropathy at the wrist (distal motor latency ≥4.5 milliseconds, wrist-digit sensory latency ≥3.5 milliseconds, or sensory conduction velocity at the carpal tunnel segment \<40 metres/second but no other abnormalities. exclusion criteria (original trial): inflammatory joint disease * diabetes mellitus, thyroid disorder, pregnancy, trauma to the affected hand during the preceding year * previous carpal tunnel release surgery in the affected hand * carpal tunnel release surgery in the contralateral hand during the preceding year * symptoms of carpal tunnel syndrome in the contralateral hand not adequately relieved by splint at the time of enrollment * current sick leave because of disorders other than carpal tunnel syndrome * inability to complete questionnaires because of language problem or cognitive disorder.

Keywords: carpal tunnel syndrome surgery outcomes
feasibility and functionality of fpam imaging in melanoma

Conditions: Melanoma

Summary: melanoma is a cutaneous malignancy that has the potential for local (skin) and regional (lymph node) recurrence. these recurrences may be difficult to detect in their earliest stages. we are attempting to use novel form of skin imaging that uses ultrasound combined with laser to identify these recurrences early, when they may be most amenable to treatment. this imaging will detect melanoma pigment below the surface of the skin and in the draining lymph nodes, as well as new blood vessel formation that occurs with these loco-regional metastases.

recruiting healthy individuals with pigmented lesions and individuals with melanoma and pigmented lesions

Eligibility criteria:
inclusion criteria: * adult patients (\> 18 yrs of age) with recently diagnosed or a history of, stage i - iii melanoma who are able to give informed consent. exclusion criteria: * patients with melanomas \< 1mm. * pregnant females. * children and young adults \< 18 yrs of age and patients who are unable to give informed consent.
association between anesthetic drugs for general anesthesia and postoperative intelligence/behavioral assessment results in children

Conditions: Anesthesia and Neurotoxicity

Summary: in this study, we compared the results of the intelligence and behavioral test performed after surgery between the group using sevoflurane and the group receiving dexmedetomidine and remifentanil, in korean children under 2 years of age who underwent surgery under general anesthesia.


Eligibility criteria:
inclusion criteria: * children under 2 years of age who underwent general anesthesia for elective surgeries inlcuding urology, surgery, plastic surgery, orthopedics, and otolaryngology, etc, which were non-staged and non-repetitive procedures * american society of anesthesiology physical status i, ii exclusion criteria: * allergies to narcotic analgesics * with massive bleeding or shock * heart, lung, kidney or liver disease * central / peripheral nervous system disease and disorder * any physical deformity and disorder, genetic disease, chromosomal disease * previous history of general anesthesia or sedation * developmental delay identified through k-dst results * additional exposure to general anesthetics or sedative drugs during follow-up
a study evaluating ro5479599 in combination with carboplatin and paclitaxel in participants with advanced or metastatic non-small-cell lung cancer (nsclc) of squamous histology

Conditions: Squamous Non-Small Cell Lung Cancer

Summary: a multi-center phase ib/ii study of the combination of ro5479599 with carboplatin and paclitaxel once in every 3 week (q3w) regimen to evaluate the safety and tolerability.


Eligibility criteria:
inclusion criteria: * participants with the eastern cooperative oncology group (ecog) performance status (ps) 0-1 * locally advanced or metastatic (stage iiib or iv) squamous nsclc * no prior systemic chemotherapy, targeted therapy for metastatic nsclc * evidence of at least one radiologically measurable lesion as per recist version 1.1 * adequate hematological, liver and renal function * participants must agree to either remain completely abstinent or to use effective contraceptive methods from screening until 6 months after the last dose of study treatment * histologically confirmed squamous nsclc participants eligible for enrollment must provide archival tumor biopsy tissue or if unavailable must be willing to undergo a fresh pretreatment primary tumor or metastatic biopsy * participants with gilbert's syndrome will be eligible for the study exclusion criteria: * concurrent therapy with any other investigational drug * history or clinical evidence of central nervous system (cns) primary tumors or metastases * evidence of significant, uncontrolled concomitant diseases, which could affect compliance with the protocol or interpretation of results, including uncontrolled diabetes mellitus and/or significant cardiovascular disease or uncontrolled infection * any other diseases, metabolic dysfunction, a physical examination finding or a clinical laboratory finding, giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug * major surgery or significant traumatic injury less than (\<) 28 days prior to the first study treatment infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment * pregnant or breast-feeding women * history of other malignancies that could affect compliance with protocol or interpretation of results. participants with malignancies diagnosed more than 5 years prior to study day one, adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer are generally eligible
stress management in breast cancer patients

Conditions: Breast Cancer; Stress

Summary: the purpose of this study within caring sciences is to identify women with breast cancer who have stress symptoms and to offer these women appropriate care to reduce stress and increase well-being. this will be achieved by 1. studying the prevalence of stress related symptoms in female patients with breast cancer 2. testing the use of two short screening instruments to identify women at risk for developing long-standing stress symptoms 3. studying the level and intensity of stress management interventions required to achieve increased well-being, using a stepped-care approach. 4. studying the effects of interventions based on cognitive behavior therapy, delivered individually or in a group format. the hypothesis is that half of the individuals assigned to a low intensity intervention will be significantly improved after treatment. for individuals who continue to have symptoms after low intensity treatment it is hypothesized that continued treatment in a group setting with high intensity interventions will be more cost-effective. in addition the assumption is that reduction of stress symptoms in women with breast cancer will lead to a reduction in socio-economic costs.


Eligibility criteria:
inclusion criteria: * over the age of 18 * a recent diagnosis of breast cancer * scheduled for adjuvant treatment in falun, gävle or uppsala (sweden) exclusion criteria: * ongoing psychiatric condition * language deficiencies in swedish

Keywords: breast cancer stress management stepped care randomized
the durability of protection study of a recombinant hpv 16/18 bivalent vaccine in female

Conditions: Cervical Intraepithelial Neoplasia; Cervical Cancer; Vaginal Intraepithelial Neoplasia; Vulvar Intraepithelial Neoplasia; Persistent Infection

Summary: the primary objective of this study is to evaluate the durability of protection of recombinant human papillomavirus bivalent (types 16,18) vaccine administered in females aged 18-45 years.

this is a follow-up study that is based on phase iii clinical study of a recombinant human papillomavirus 16/18 bivalent vaccine in females aged 18-45 years (unique protocol id: hpv-pro-003, identifiers: nct01735006). the investigators will recruit people who have participated in phase iii clinical study on hebei province before and to evaluate the durability of protection of the bivalent hpv vaccine on 90m and 114m after dose 1.

Eligibility criteria:
inclusion criteria: 1. participants who participated in the phase iii clinical study of a recombinant human papillomavirus 16/18 bivalent vaccine in females (unique protocol id: hpv-pro-003, identifiers: nct01735006) and received at least one dose; 2. participants can fully understand the study content and sign an informed consent form； 3. able to comply with the requests of the study; exclusion criteria: 1. participants used other hpv vaccine products (including both marketed and unmarketed vaccines) since participating in the phase iii clinical study. 2. according to the investigator's judgment, there might be some medical, psychological, social or occupational factors which might impact on the individual to obey the protocol or sign the informed consent;

Keywords: durability of protection human papillomavirus 16 human papillomavirus 18 vaccine females
the efficacy and safety of sanfujiu on patients with persistent allergic rhinitis: randomized controlled study

Conditions: Allergic Rhinitis

Summary: the purpose of this study is to determine whether sanfujiu is effective and safe in the treatment of persistent allergic rhinitis.

the trial consists of 5 treatment sessions along with a one-year follow-up. this process is then repeated in the second and third years. eligible participants diagnosed with par were randomized at a ratio of 2:2:1 into one of three groups: (a) shp group; (b) placebo group; or (c) waiting-list group. the waiting-list group will receive no treatment in the first year, but will receive shp in the following two years. the primary outcome, total nasal symptoms score, is self-assessed at the beginning of each treatment session and during each annual follow-up. secondary outcomes include the rhinoconjunctivitis quality of life questionnaire, allergic rhinitis attacks, and relief medications. the trial will be stopped if early termination criteria are met during the interim analysis.

Eligibility criteria:
inclusion criteria: * aged ≥18 with par, defined clinically as symptoms being present at least 4 days a week, for at least 4 weeks * test positive for allergen specific immunoglobulin e . allergens include: mites (dermatophagoides pteronyssinus and dermatophagoides farinae), cockroach (blatella germanica) and/or house dust * informed consent * tnss ≥3 exclusion criteria: * seasonal or chronic instance of other forms of rhinitis (i.e. sinusitis) * asthma and/or moderate to severe atopic dermatitis * allergy treatment at present due to asthma, eczema, atopic dermatitis, or other diseases * nasal structural abnormalities * severe mental illness, severe chronic respiratory diseases, severe diseases of the cardiovascular system, severe kidney disease, severe liver disease, severe blood system diseases, severe neurological and neuromuscular disease, severe metabolic and endocrine system disease, severe diabetes, immune function (including the application of immunosuppressant or hiv infection to low immune function etc.); the laboratory test indexes more than twice the upper limit of normal reference value or abnormal results that don't fit for the study confirmed by researchers; * blood coagulation dysfunction or patients are using anticoagulants * systemic corticosteroids treatment six months before the start of the study, or intranasal corticosteroids 15 days before the start of the study; * immunotherapy for more than 3 years; * alternative therapies such as acupuncture, traditional chinese medicine (tcm) one month before the start of the study,or prepare to use during the study; * moxibustion therapy half years before the start of the study; * patients participating other clinical trials; * prepare to pregnancy, pregnancy or lactation
erenumab for treatment of hemicrania continua

Conditions: Hemicrania Continua

Summary: this research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua. the study is also evaluating the safety and tolerability of erenumab in individuals being treated for hemicrania continua.


Eligibility criteria:
inclusion criteria * adults over the age of 18-66 * at least a 12 month history of hemicrania continua (unremitting subtype) according to international classification of headache disorders, 3rd edition (ichd-3)1 * previous or current complete response to indomethacin * stable preventive treatment for at least 2 months and no anticipated need to adjust/add current headache prevention treatment exclusion criteria * nonresponse to a therapeutic dose of indomethacin for hemicrania continua when used for at least 1 week * pregnant or lactating subjects * use of barbiturate or opioid \>6 days per month; history of chronic migraine * history of previous trigeminal-autonomic cephalalgia * history within previous 2 months of interventional procedure for headache (occipital or other extracranial nerve block, sphenopalatine ganglion block, cervical facet block, facet rhizotomy) * history of cranial nerve/rhizolysis * botulinumtoxin injection with previous 4 months * parenteral infusion of or oral corticosteroid use for more than 3 days within 4 weeks prior to screening phase
treatment of drooling with type a botulinum toxin in children with cerebral palsy

Conditions: Cerebral Palsy; Drooling

Summary: the purpose of this study is to evaluate the effectiveness of botulinum toxin injection to treat drooling in children with cerebral palsy, and to find the most appropriate dosage, duration of effect and side effects.

sialorrhea, or drooling, has been reported to be a significant problem in 10%to 37% of patients with cerebral palsy. excessive drooling may cause skin maceration, increased the burden of caregiver, affect articulation of the patients, and increase the risk of aspiration and dehydration. many options, including various therapies, medications, surgeries and radiation, have been proposed to treat drooling. yet none of these is universally successful and many have potential complications. nerve endings of the parasympathetic post-ganglionic neurons secret aceylcholine. botulinum toxin should be able to inhibit salivary gland secretion by blocking the release of acetylcholine. very limited case series had proved fair result of botulinum toxin injection to treat drooling. however, most of the subjects were adult patients with neurological disorders. the purpose of this study is to evaluate the effectiveness of botulinum toxin injection to treat drooling in children with cerebral palsy, and to find the most appropriate dosage, duration of effect and side effects.

Eligibility criteria:
inclusion criteria: * diagnosis of cerebral palsy * severe drooling * aged 6-21 yrs * subjects (or their guardian) who are able to understand the requirements of the study and sign the informed consent form exclusion criteria: * age below 6 yrs or above 21 yrs * known allergy or sensitivity to the study medication or its component * diagnosis of myasthenia gravis, amyotrophic lateral sclerosis or any other disease that might interfere with neuromuscular function * subjects who have prior surgery of the submandibular gland * subjects who are receiving medication that affect drooling such as anticholinergic drug * inability to give informed consent

Keywords: cerebral palsy drooling botulinum toxin
progesterone supplementation in frozen embryo transfer cycles

Conditions: Infertility Due to Nonimplantation; Infertility

Summary: recurrent implantation failure (rif) occurs after women undergo in vitro fertilization and have multiple embryos transferred but no resulting pregnancies. rif is a very challenging clinical entity for the reproductive physician and the patient. in fact, there is not even an agreed upon definition in the medical community. many potential causes have been investigated over the past several years but no clear answer has emerged. interest has recently turned to the endometrium, or the lining of the uterus. studies have shown that the genes that are turned on in the endometrium vary based on how long this tissue has been exposed to progesterone, an important hormone that prepares the uterine lining for implantation of the growing embryo. in some women, it seems that they require longer periods of progesterone exposure to reach the same state of readiness. we hypothesize that an even larger proportion of women in rif population will require longer treatments with progesterone. in this study, we will randomize women with rif who are about to undergo a frozen embryo transfer to one of two groups. the first group will have their embryo transfer done on the standard sixth day of progesterone treatment. the other group will have their transfer done on the seventh day of progesterone. we will be comparing the clinical pregnancy rate of the two groups as well as the live birth rate and miscarriage rate. we expect that extending the progesterone treatment by one day will increase the pregnancy rate of women with rif.


Eligibility criteria:
inclusion criteria: * patient at mount sinai fertility who wants to undertake a frozen embryo transfer * history of recurrent implantation failure, defined as no pregnancy after three or more embryo transfers of four or more good quality blastocysts exclusion criteria: * previous testing with endometrial receptivity assay (era) * unable understand/communicate in english